Evoke Pharma Inc. (NASDAQ:EVOK) saw an uptick in trading volume on Monday . 7,714,380 shares were traded during mid-day trading, an increase of 1,425% from the previous session’s volume of 505,870 shares.The stock last traded at $3.11 and had previously closed at $10.73.

A number of brokerages have weighed in on EVOK. FBR & Co restated a “buy” rating on shares of Evoke Pharma in a report on Saturday, May 14th. Zacks Investment Research cut shares of Evoke Pharma from a “buy” rating to a “hold” rating in a report on Thursday, May 5th. Noble Financial cut shares of Evoke Pharma from a “buy” rating to a “hold” rating in a report on Tuesday. Brean Capital restated a “buy” rating on shares of Evoke Pharma in a report on Thursday, May 12th. Finally, Rodman & Renshaw restated a “buy” rating on shares of Evoke Pharma in a report on Thursday, May 12th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the company’s stock. Evoke Pharma has an average rating of “Hold” and an average price target of $13.34.

The stock’s market cap is $16.43 million. The stock has a 50-day moving average of $6.59 and a 200 day moving average of $4.81.

Evoke Pharma (NASDAQ:EVOK) last released its earnings results on Wednesday, May 11th. The specialty pharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by $0.04. Analysts forecast that Evoke Pharma Inc. will post ($1.41) EPS for the current year.

In related news, major shareholder Parters Vii L. P. Domain sold 344,120 shares of Evoke Pharma stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $4.70, for a total transaction of $1,617,364.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Parters Vii L. P. Domain sold 5,095 shares of Evoke Pharma stock in a transaction dated Wednesday, April 27th. The shares were sold at an average price of $5.07, for a total transaction of $25,831.65. The disclosure for this sale can be found here.

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.